Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CBX7 | O95931 | 1/20 | 0.50 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.50 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.50 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.50 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.50 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL474524 | 0.86 | TSHR (0.56) | TSHRMEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL24855242 | 0.80 | TSHR (0.44) | TSHRMEN1KMT2AL3MBTL1CBX7 | |
| SCHEMBL474614 | 0.80 | TSHR (0.60) | TSHRMEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL10530282 | 0.79 | CHRM1 (0.49) | TSHRALDH1A1KDM4EGAAMAPT | |
| SCHEMBL15690661 | 0.77 | ALDH1A1 (0.58) | TSHRMEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL9214610 | 0.77 | ALDH1A1 (0.58) | TSHRMEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL7358743 | 0.77 | ALDH1A1 (0.61) | TSHRMEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL3641417 | 0.77 | ALDH1A1 (0.58) | TSHRMEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL10374294 | 0.76 | TSHR (0.56) | TSHRMEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL4970176 | 0.76 | KMT2A (0.68) | TSHRMEN1KMT2AALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2917194-B1 | NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS | LILLY CO ELI (US) | 2017-09-27 | — | — | EP | disclosed |
| EP-2917194-B1 | NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS | LILLY CO ELI (US) | 2017-09-27 | — | — | EP | disclosed |
| US-9416138-B2 | Benzyl sulfonamide compounds useful as MoGAT-2 inhibitors | ELI LILLY AND COMPANY (US) | 2016-08-16 | — | — | US | disclosed |
| US-9416138-B2 | Benzyl sulfonamide compounds useful as MoGAT-2 inhibitors | ELI LILLY AND COMPANY (US) | 2016-08-16 | — | — | US | disclosed |
| US-9416138-B2 | Benzyl sulfonamide compounds useful as MoGAT-2 inhibitors | ELI LILLY AND COMPANY (US) | 2016-08-16 | — | — | US | disclosed |
| US-20150284404-A1 | NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS | ELI LILLY AND COMPANY | 2015-10-08 | — | — | US | disclosed |
| US-20150284404-A1 | NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS | ELI LILLY AND COMPANY | 2015-10-08 | — | — | US | disclosed |
| US-20150284404-A1 | NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS | ELI LILLY AND COMPANY | 2015-10-08 | — | — | US | disclosed |
| EP-2917194-A1 | NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS | Eli Lilly and Company (US) | 2015-09-16 | — | — | EP | disclosed |
| US-8759342-B2 | Benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one urotensin II receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-24 | — | — | US | disclosed |
| US-8759342-B2 | Benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one urotensin II receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-24 | — | — | US | disclosed |
| US-8759342-B2 | Benzo[1,4]oxazin-3-one, benzo[1,4]thiazin-3-one and quinolin-2-one urotensin II receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-24 | — | — | US | disclosed |
| WO-2014074365-A1 | NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2014-05-15 | — | — | WO | disclosed |
| WO-2014074365-A1 | NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2014-05-15 | — | — | WO | disclosed |
| EP-2049120-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2009-04-22 | — | — | EP | disclosed |
| US-20080039454-A1 | Urotensin II receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-02-14 | — | — | US | disclosed |
| WO-2008016534-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008016534-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284404-A1 | NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS | MOGAT2, SOAT1, SOAT2 | TSHR 2001/4885MEN1 1241/4885KMT2A 132/4885 |
| US-20080039454-A1 | Urotensin II receptor antagonists | UTS2R, PLAUR, NTSR2 | TSHR 527/4885MEN1 2791/4885KMT2A 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.